Takeda Pharmaceutical stock
TAKNYSETakeda Pharmaceutical Company Limited, HealthcareISIN US8740602052
57Score 57 out of 100, Neutral
Price and trend
81 / 100
Price history
+50% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is at its 52-week high. Largest decline in 19 years: 60% (January 2018 to October 2022).
Chart figures for advanced users
- SMA 50$19.34
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.06
- The lowest closing price of the last twelve months.
- Resistance$21.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Takeda Pharmaceutical Company Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (Japan) and, with a market value of $68.97B, is number 2 of 78 companies in its industry on MEQIRI.
- American depositary receipt (ADR): 2 ADRs = 1 share.
- In fiscal 2025 it reported revenue of $28.3B (down 1.7% year on year) and a loss of $957.08M.
Show more
- MEQIRI Score 57 out of 100 (Neutral): rank 322 of 714 in Healthcare, median 53.
- The P/E is 252.6 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 40.4).
- Our model puts fair value at $5.69, with the price 266% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 72
- High dividend yieldDividend yield 3.38%, Drug Manufacturers (Specialty & Generic) median 1.74%.
Weaknesses
- Richly valuedP/E 252.6, Drug Manufacturers (Specialty & Generic) median 19.3, own median 40.4.Valuation 20
- Above fair valuePrice 266% above the fair value of $5.69.Valuation 20
- Turned to a lossEarnings per share from $0.76 in 2020 to −$0.30.Growth 27
Its standout strengths are momentum and technical analysis, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.07 and expensive above $9.49 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $9.77 (cash-flow model) and $1.62 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $4.99, at 5.1% it would be $6.73.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7.2% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating 13%, net −3%. Last 12 months: net 8%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 29 Oct 2026above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 23.5% since 15 Oct 2026.
- Earnings per share
- 76.45+23.5%
- Revenue
- $29.68B+0.8%
- Earnings per share
- 102.52+3.4%
- Revenue
- $30.28B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.8%Takeda raised its management guidance for core operating profit and core EPS, mainly due to favorable currency effects, while keeping its revenue guidance at a low single-digit percentage decline.
“Starting with management guidance for CER growth, we maintain our revenue guidance of low single-digit percent decline.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 13 insiders sold, $15.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Platford Giles RichardSale
4 Nov 2026, President, IBU
- Shares
- 27,808.5
- Price
- $41.80
- Value
- $1.16M
- Bitetti Teresa MarieSale
2 Nov 2026, President, OBU
- Shares
- 23,304.5
- Price
- $41.78
- Value
- $973,662
- Duprey Lauren RusckowskiSale
14 Sept 2026, Chief Transformation Officer
- Shares
- 17,267.5
- Price
- $37.08
- Value
- $640,279
Show 19 more
- Plump Andrew StewartSale
2 Sept 2026, President, R&D
- Shares
- 58,095.5
- Price
- $36.98
- Value
- $2.15M
- Plump Andrew StewartSale
19 Aug 2026, President, R&D
- Shares
- 9,825.5
- Price
- $36.98
- Value
- $363,347
- Greenway Nicola Deidre PetalSale
18 Aug 2026, Chief Human Resources Officer
- Shares
- 6,490
- Price
- $36.23
- Value
- $235,118
- Shannon Elaine MarySale
11 Aug 2026, Pres., Global Supply & Quality
- Shares
- 10,181.5
- Price
- $35.10
- Value
- $357,371
- Farajallah Awny Samaan BotrosSale
10 Aug 2026, Chief Medical Officer
- Shares
- 7,003
- Price
- $34.20
- Value
- $239,503
- Ibrahim Ramy Riad AhmedSale
10 Aug 2026, President, PDT BU
- Shares
- 3,638.5
- Price
- $34.20
- Value
- $124,437
- Pacheco Rhonda JaniceSale
10 Aug 2026, President, U.S. Business Unit
- Shares
- 8,450.5
- Price
- $34.20
- Value
- $289,007
- Duprey Lauren RusckowskiSale
10 Aug 2026, Chief Transformation Officer
- Shares
- 23,793
- Price
- $34.20
- Value
- $813,721
- Plump Andrew StewartSale
10 Aug 2026, President, R&D
- Shares
- 82,696.5
- Price
- $34.20
- Value
- $2.83M
- Pignagnoli Agosti MarcelloSale
10 Aug 2026, Head, Strat. & Port. Dev
- Shares
- 11,478.5
- Price
- $34.20
- Value
- $392,565
- Bitetti Teresa MarieSale
10 Aug 2026, President, OBU
- Shares
- 25,006
- Price
- $34.20
- Value
- $855,205
- Shannon Elaine MarySale
10 Aug 2026, Pres., Global Supply & Quality
- Shares
- 1,989
- Price
- $34.20
- Value
- $68,024
- Ricci GabrieleSale
10 Aug 2026, Chief Data & Tech. Officer
- Shares
- 12,544
- Price
- $34.20
- Value
- $429,005
- Greenway Nicola Deidre PetalSale
10 Aug 2026, Chief Human Resources Officer
- Shares
- 3,387
- Price
- $34.20
- Value
- $115,835
- Kim Julie So-YoungSale
10 Aug 2026, President and CEO
- Shares
- 44,545
- Price
- $34.20
- Value
- $1.52M
- Platford Giles RichardSale
10 Aug 2026, President, IBU
- Shares
- 15,541.5
- Price
- $34.20
- Value
- $531,519
- Furney Natalie Anne MarieSale
10 Aug 2026, Global General Counsel
- Shares
- 15,434
- Price
- $34.20
- Value
- $527,843
- Greenway Nicola Deidre PetalSale
10 Aug 2026, Chief Human Resources Officer
- Shares
- 487.5
- Price
- $35.00
- Value
- $17,063
- Greenway Nicola Deidre PetalSale
10 Aug 2026, Chief Human Resources Officer
- Shares
- 16,814
- Price
- $35.01
- Value
- $588,715
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt (2 ADRs = 1 share). Filings per depositary receipt are converted to ordinary shares.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Takeda Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Merck KGaAMRK.DE $73.34B68
- Galderma GroupGALD.SW $54.78B64
- Teva Pharmaceutical IndustriesTEVA $50.45B54
- Sun Pharmaceutical IndustriesSUNPHARMA.NS $48.71B72
- Jiangsu Hengrui Medicine600276.SS $46.11B70
- Sandoz GroupSDZ.SW $44.42B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.51B67
- HaleonHLN $40.35B61
ETFs that hold Takeda Pharmaceutical
Held by 102 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Japan SRI Climate Paris Aligned UCITS ETF DR Hedged EUR (D)JPNE | 2.66% | 0.20% | €500.27M |
| iShares MSCI Japan CTB Enhanced ESG UCITS ETF EUR Hedged AccCEB3 | 2.63% | 0.18% | €114.27M |
| Amundi MSCI Japan ESG Broad Transition UCITS ETF EUR AccJ1GR | 2.34% | 0.15% | €1.31B |
Show 5 more
| Deka MSCI Japan Climate Change ESG UCITS ETFEL45 | 2.02% | 0.26% | €162.3M |
| WisdomTree Japan Equity UCITS ETF USD HedgedWTDX | 1.90% | 0.48% | €796.64M |
| JPM Global Equity Premium Income Active UCITS ETF USD (dist)JGPI | 1.61% | 0.35% | €1.55B |
| Xtrackers MSCI Japan Screened UCITS ETF 3C EUR HedgedXDNE | 1.50% | 0.25% | €453.13M |
| iShares Edge MSCI World Minimum Volatility Advanced UCITS ETF USD (Acc)MVEW | 1.47% | 0.30% | €306.37M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ¥159.23)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.